Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Cytek BioSciences Inc (NASDAQ: CTKB) closed the day trading at $4.17 up 3.47% from the previous closing price of $4.03. In other words, the price has increased by $3.47 from its previous closing price. On the day, 1.35 million shares were traded. CTKB stock price reached its highest trading level at $4.185 during the session, while it also had its lowest trading level at $4.035.
Ratios:
For a better understanding of CTKB, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.02 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 48.81. For the most recent quarter (mrq), Quick Ratio is recorded 4.55 and its Current Ratio is at 5.22. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.06.
On January 31, 2025, Goldman Downgraded its rating to Sell which previously was Buy and also lowered its target price recommendation from $7 to $4.50.
On December 14, 2023, Stephens started tracking the stock assigning a Overweight rating and target price of $9.Stephens initiated its Overweight rating on December 14, 2023, with a $9 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 02 ’25 when McCombe William D. bought 35,000 shares for $2.78 per share. The transaction valued at 97,300 led to the insider holds 55,746 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTKB now has a Market Capitalization of 530524096 and an Enterprise Value of 292181152. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.71 while its Price-to-Book (P/B) ratio in mrq is 1.40. Its current Enterprise Value per Revenue stands at 1.49 whereas that against EBITDA is -13.286.
Stock Price History:
The Beta on a monthly basis for CTKB is 1.35, which has changed by -0.22920519 over the last 52 weeks, in comparison to a change of 0.16657472 over the same period for the S&P500. Over the past 52 weeks, CTKB has reached a high of $7.63, while it has fallen to a 52-week low of $2.37. The 50-Day Moving Average of the stock is 19.88%, while the 200-Day Moving Average is calculated to be -9.61%.
Shares Statistics:
Over the past 3-months, CTKB traded about 1.30M shares per day on average, while over the past 10 days, CTKB traded about 1443390 shares per day. A total of 127.19M shares are outstanding, with a floating share count of 115.12M. Insiders hold about 9.52% of the company’s shares, while institutions hold 58.10% stake in the company. Shares short for CTKB as of 1753920000 were 5098722 with a Short Ratio of 3.93, compared to 1751241600 on 4741336. Therefore, it implies a Short% of Shares Outstanding of 5098722 and a Short% of Float of 5.21.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Cytek BioSciences Inc (CTKB) reflects the combined expertise of 2.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.04, with high estimates of $0.04 and low estimates of $0.03.
Analysts are recommending an EPS of between $0.04 and $0.03 for the fiscal current year, implying an average EPS of $0.04. EPS for the following year is $0.03, with 2.0 analysts recommending between $0.05 and $0.01.
Revenue Estimates
4 analysts predict $51.49M in revenue for the current quarter. It ranges from a high estimate of $52.7M to a low estimate of $51.03M. As of the current estimate, Cytek BioSciences Inc’s year-ago sales were $51.5MFor the next quarter, 4 analysts are estimating revenue of $57.24M. There is a high estimate of $58.46M for the next quarter, whereas the lowest estimate is $55M.
A total of 5 analysts have provided revenue estimates for CTKB’s current fiscal year. The highest revenue estimate was $196.65M, while the lowest revenue estimate was $195.5M, resulting in an average revenue estimate of $196.18M. In the same quarter a year ago, actual revenue was $200.45MBased on 5 analysts’ estimates, the company’s revenue will be $210.48M in the next fiscal year. The high estimate is $213.6M and the low estimate is $203.3M.
